• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

替格列汀治疗后出现弥漫性红斑疹：一例报告。

Diffuse erythematous rash after teneligliptin therapy: A case report.

作者信息

Agrawal Prabhat, Jain Apoorv, Bansal Saurabh, Raj Abhishek

机构信息

Department of Medicine, S.N. Medical College, Agra, Uttar Pradesh, India.

出版信息

J Family Med Prim Care. 2018 Nov-Dec;7(6):1571-1572. doi: 10.4103/jfmpc.jfmpc_283_18.

DOI:10.4103/jfmpc.jfmpc_283_18
PMID:30613561
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC6293926/
Abstract

We report a yet unreported, adverse effect of teneligliptin [Dipeptidyl peptidase IV inhibitor (DPP IV)] presenting as diffuse pruritic erythematous rash, in a patient, 2 days after initiation of the drug. The rash waned off after the discontinuation of the drug without any residual lesion.

摘要

我们报告了一例在开始使用替格列汀[二肽基肽酶IV抑制剂（DPP IV）]两天后出现弥漫性瘙痒性红斑皮疹的未报道过的不良反应。停药后皮疹消退，未留下任何痕迹。

相似文献

1
Diffuse erythematous rash after teneligliptin therapy: A case report.替格列汀治疗后出现弥漫性红斑疹：一例报告。
J Family Med Prim Care. 2018 Nov-Dec;7(6):1571-1572. doi: 10.4103/jfmpc.jfmpc_283_18.
2
Multicenter prospective observational study of teneligliptin, a selective dipeptidyl peptidase-4 inhibitor, in patients with poorly controlled type 2 diabetes: Focus on glycemic control, hypotensive effect, and safety Chikushi Anti-Diabetes Mellitus Trial-Teneligliptin (CHAT-T).多中心前瞻性观察研究西格列汀，一种选择性二肽基肽酶-4 抑制剂，在血糖控制不佳的 2 型糖尿病患者中的应用：关注血糖控制、降压作用和安全性——日本九州地区抗糖尿病试验-西格列汀（CHAT-T）。
Clin Exp Hypertens. 2020;42(3):197-204. doi: 10.1080/10641963.2019.1601207. Epub 2019 Apr 11.
3
Teneligliptin, a DPP-4 Inhibitor, Decreases Plasma Levels of Inflammatory Chemokines During a Standard Meal Test in Patients With Type 2 Diabetes.替格列汀，一种 DPP-4 抑制剂，可降低 2 型糖尿病患者标准餐试验期间的炎症趋化因子的血浆水平。
Am J Med Sci. 2020 Sep;360(3):261-267. doi: 10.1016/j.amjms.2020.05.005. Epub 2020 May 11.
4
A novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor, teneligliptin, improves postprandial hyperglycemia and dyslipidemia after single and repeated administrations.一种新型强效且持久的二肽基肽酶-4 抑制剂，替格列汀，可改善单次和多次给药后的餐后高血糖和血脂异常。
Eur J Pharmacol. 2012 Dec 5;696(1-3):194-202. doi: 10.1016/j.ejphar.2012.09.024. Epub 2012 Sep 26.
5
Effect of switching to teneligliptin from other dipeptidyl peptidase-4 inhibitors on glucose control and renoprotection in type 2 diabetes patients with diabetic kidney disease.在患有糖尿病肾病的 2 型糖尿病患者中，从其他二肽基肽酶-4 抑制剂转换为替格列汀对血糖控制和肾脏保护的影响。
J Diabetes Investig. 2019 May;10(3):706-713. doi: 10.1111/jdi.12917. Epub 2018 Oct 1.
6
Ameliorating effect of the novel dipeptidyl peptidase-4 inhibitor teneligliptin on psoriasis: A report of two cases.新型二肽基肽酶-4抑制剂替格列汀对银屑病的改善作用：两例报告
J Dermatol. 2015 Nov;42(11):1094-7. doi: 10.1111/1346-8138.12955. Epub 2015 May 28.
7
Efficacy and Safety of Switching to Teneligliptin in Patients with Type 2 Diabetes Inadequately Controlled with Dipeptidyl Peptidase-4 Inhibitors: 52-Week Results from a Prospective Observational Study.二肽基肽酶-4抑制剂控制不佳的2型糖尿病患者换用替奈利肽的疗效和安全性：一项前瞻性观察性研究的52周结果
Diabetes Ther. 2021 Nov;12(11):2907-2920. doi: 10.1007/s13300-021-01148-1. Epub 2021 Sep 18.
8
A novel DPP-4 inhibitor teneligliptin scavenges hydroxyl radicals: In vitro study evaluated by electron spin resonance spectroscopy and in vivo study using DPP-4 deficient rats.新型二肽基肽酶-4抑制剂替格列汀可清除羟自由基：通过电子自旋共振光谱进行的体外研究及使用二肽基肽酶-4缺陷大鼠进行的体内研究
Metabolism. 2016 Mar;65(3):138-45. doi: 10.1016/j.metabol.2015.10.030. Epub 2015 Nov 2.
9
Suppression of Abdominal Aortic Aneurysm Formation in Mice by Teneligliptin, a Dipeptidyl Peptidase-4 Inhibitor.西格列汀，一种二肽基肽酶-4 抑制剂，抑制小鼠的腹主动脉瘤形成。
J Atheroscler Thromb. 2018 Aug 1;25(8):698-708. doi: 10.5551/jat.42481. Epub 2018 Jan 10.
10
Real-World Evidence of Treatment with Teneligliptin/Canagliflozin Combination Tablets for Type 2 Diabetes Mellitus: A Post-Marketing Surveillance in Japan.真实世界中替格列汀/卡格列净复方片剂治疗 2 型糖尿病的证据：日本上市后监测。
Adv Ther. 2022 Apr;39(4):1642-1658. doi: 10.1007/s12325-021-02038-5. Epub 2022 Feb 9.

引用本文的文献

1
Exanthematous Drug Eruption as a Side Effect of Teneligliptin.作为替格列汀副作用的药疹
Indian J Endocrinol Metab. 2021 Sep-Oct;25(5):470-471. doi: 10.4103/ijem.ijem_326_21. Epub 2022 Jan 12.

本文引用的文献

1
Teneligliptin: An Economic and Effective DPP-4 Inhibitor for the Management of Type-2 Diabetes Mellitus: A Comparative Study.替奈利汀：一种用于治疗2型糖尿病的经济有效的二肽基肽酶-4抑制剂：一项比较研究。
J Assoc Physicians India. 2018 Aug;66(8):67-69.
2
Teneligliptin real-world efficacy assessment of type 2 diabetes mellitus patients in India (TREAT-INDIA study).在印度对2型糖尿病患者进行的替奈利肽真实世界疗效评估（TREAT-INDIA研究）。
Diabetes Metab Syndr Obes. 2016 Nov 8;9:347-353. doi: 10.2147/DMSO.S121770. eCollection 2016.
3
Drug-induced generalized skin eruption in a diabetes mellitus patient receiving a dipeptidyl peptidase-4 inhibitor plus metformin.二肽基肽酶-4 抑制剂联合二甲双胍致糖尿病患者泛发性皮肤疹。
Diabetes Ther. 2012 Dec;3(1):14. doi: 10.1007/s13300-012-0014-7. Epub 2012 Nov 6.
4
Weight neutrality with the DPP-4 inhibitor, vildagliptin: mechanistic basis and clinical experience.二肽基肽酶-4抑制剂维格列汀的体重中性：作用机制及临床经验
Vasc Health Risk Manag. 2010 Aug 9;6:541-8. doi: 10.2147/vhrm.s10952.
5
Diabetes-related microvascular and macrovascular diseases in the physical therapy setting.物理治疗环境中与糖尿病相关的微血管和大血管疾病。
Phys Ther. 2008 Nov;88(11):1322-35. doi: 10.2522/ptj.20080008. Epub 2008 Sep 18.